Kamal Shemisa1, Anish Bhatt1, Daniel Cheeran1, Ian J Neeland2. 1. Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-8830, USA. 2. Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-8830, USA. ian.neeland@utsouthwestern.edu.
Abstract
PURPOSE OF REVIEW: Recognition of subclinical myocardial dysfunction offers clinicians and patients an opportunity for early intervention and prevention of symptomatic cardiovascular disease. We review the data on novel biomarkers in subclinical heart disease in the general population with a focus on pathophysiology, recent observational or trial data, and potential applicability and pitfalls for clinical use. RECENT FINDINGS: High-sensitivity cardiac troponin and natriuretic peptide assays are powerful markers of subclinical cardiac disease. Elevated levels of these biomarkers signify subclinical cardiac injury and hemodynamic stress and portend an adverse prognosis. Novel biomarkers of myocardial inflammation, fibrosis, and abnormal contraction are gaining momentum as predictors for incident heart failure, providing new insight into pathophysiologic mechanisms of cardiac disease. There has been exciting growth in both traditional and novel biomarkers of subclinical cardiac injury in recent years. Many biomarkers have demonstrated associations with relevant cardiovascular outcomes and may enhance the diagnostic and prognostic power of more conventional biomarkers. However, their use in "prime time" to identify patients with or at risk for subclinical cardiac dysfunction in the general population remains an open question. Strategic investigation into their clinical applicability in the context of clinical trials remains an area of ongoing investigation.
PURPOSE OF REVIEW: Recognition of subclinical myocardial dysfunction offers clinicians and patients an opportunity for early intervention and prevention of symptomatic cardiovascular disease. We review the data on novel biomarkers in subclinical heart disease in the general population with a focus on pathophysiology, recent observational or trial data, and potential applicability and pitfalls for clinical use. RECENT FINDINGS: High-sensitivity cardiac troponin and natriuretic peptide assays are powerful markers of subclinical cardiac disease. Elevated levels of these biomarkers signify subclinical cardiac injury and hemodynamic stress and portend an adverse prognosis. Novel biomarkers of myocardial inflammation, fibrosis, and abnormal contraction are gaining momentum as predictors for incident heart failure, providing new insight into pathophysiologic mechanisms of cardiac disease. There has been exciting growth in both traditional and novel biomarkers of subclinical cardiac injury in recent years. Many biomarkers have demonstrated associations with relevant cardiovascular outcomes and may enhance the diagnostic and prognostic power of more conventional biomarkers. However, their use in "prime time" to identify patients with or at risk for subclinical cardiac dysfunction in the general population remains an open question. Strategic investigation into their clinical applicability in the context of clinical trials remains an area of ongoing investigation.
Authors: Christopher R deFilippi; James A de Lemos; Robert H Christenson; John S Gottdiener; Willem J Kop; Min Zhan; Stephen L Seliger Journal: JAMA Date: 2010-11-15 Impact factor: 56.272
Authors: John W McEvoy; Yuan Chen; Chiadi E Ndumele; Scott D Solomon; Vijay Nambi; Christie M Ballantyne; Roger S Blumenthal; Josef Coresh; Elizabeth Selvin Journal: JAMA Cardiol Date: 2016-08-01 Impact factor: 14.676
Authors: John W McEvoy; Yuan Chen; Andreea Rawlings; Ron C Hoogeveen; Christie M Ballantyne; Roger S Blumenthal; Josef Coresh; Elizabeth Selvin Journal: J Am Coll Cardiol Date: 2016-08-30 Impact factor: 24.094
Authors: Gaby Palmer; Brian P Lipsky; Molly D Smithgall; David Meininger; Sophia Siu; Dominique Talabot-Ayer; Cem Gabay; Dirk E Smith Journal: Cytokine Date: 2008-05-02 Impact factor: 3.861
Authors: Luigi Gabrielli; Jose L Winter; Ivan Godoy; Paul McNab; Ivonne Padilla; Samuel Cordova; Paola Rigotti; Ulises Novoa; Italo Mora; Lorena García; Maria P Ocaranza; Jorge E Jalil Journal: Am J Hypertens Date: 2013-12-21 Impact factor: 2.689
Authors: Parul U Gandhi; Hanna K Gaggin; Alex D Sheftel; Arianna M Belcher; Rory B Weiner; Aaron L Baggish; Shweta R Motiwala; Peter P Liu; James L Januzzi Journal: Am J Cardiol Date: 2014-08-27 Impact factor: 2.778
Authors: Ragnhild Røysland; Marc P Bonaca; Torbjørn Omland; Marc Sabatine; Sabina A Murphy; Benjamin M Scirica; Mette Bjerre; Allan Flyvbjerg; Eugene Braunwald; David A Morrow Journal: Heart Date: 2012-02-28 Impact factor: 5.994
Authors: Macy M S Lui; H F Tse; Judith C W Mak; David C L Lam; Carmen W S Chan; Peony W C Chong; Mary S M Ip Journal: J Clin Sleep Med Date: 2018-11-15 Impact factor: 4.062
Authors: Vinithra Varadarajan; Bharath Ambale-Venkatesh; Seo Young Hong; Mohammadali Habibi; Hiroshi Ashikaga; Colin O Wu; Lin Y Chen; Susan R Heckbert; David A Bluemke; Joao A C Lima Journal: Am J Hypertens Date: 2021-06-22 Impact factor: 3.080